Dublin, Jan. 23, 2017 -- Research and Markets has announced the addition of the "Needle Free Drug Delivery Market Analysis & Trends - Product - Forecast to 2025" report to their offering.
Global Needle Free Drug Delivery Market is poised to grow at a CAGR of around 10.5% over the next decade to reach approximately $16.12 billion by 2025.
Some of the prominent trends that the market is witnessing include rising cases of chronic diseases had boasted demand for drug delivery, growing bio-pharmaceuticals across the globe, recent technological developments of needle free drug delivery and growth opportunities/investment opportunities.
Based on product type, the market is categorized into nanopatches, electronically assisted transport, microneedles, iontophoresis and intranasal.
Depending on the technology, the market is segmented into oral drug delivery system, inhaler technology, laser-based needle-free injectors, jet injectors, novel needle free technologies, spring-based needle-free injectors, transdermal patch technology and other needle-free technologies.
By application, the market is further segregated into pain management, insulin delivery for diabetes, vaccine delivery, pediatric injections, obstructive sleep apnea and other applications. By other applications, the market is further classified into angina, hypertension and other medical conditions.
This industry report analyzes the global markets for Needle Free Drug Delivery across all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2013, 2014 revenue estimations are presented for 2015 and forecasts from 2016 till 2025.
The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.
Key Topics Covered:
1 Market Outline
2 Executive Summary
3 Market Overview
3.1 Current Trends
3.1.1 Rising cases of Chronic Diseases had boasted demand for drug delivery
3.1.2 Growing Bio-pharmaceuticals across the globe
3.1.3 Recent Technological Developments Of Needle Free Drug Delivery
3.1.4 Growth Opportunities/Investment Opportunities
3.2 Drivers
3.3 Constraints
3.4 Industry Attractiveness
3.4.1 Bargaining power of suppliers
3.4.2 Bargaining power of buyers
3.4.3 Threat of substitutes
3.4.4 Threat of new entrants
3.4.5 Competitive rivalry
4 Needle Free Drug Delivery Market, By Product
4.1 Nanopatches
4.2 Electronically Assisted Transport
4.3 Microneedles
4.4 Iontophoresis
4.5 Intranasal
5 Needle Free Drug Delivery Market, By Technology
5.1 Oral Drug Delivery System
5.2 Inhaler Technology
5.3 Laser-based Needle-free Injectors
5.4 Jet Injectors
5.5 Novel Needle Free Technologies
5.6 Spring-based Needle-free Injectors
5.7 Transdermal Patch Technology
5.8 Other Needle-free Technologies
6 Needle Free Drug Delivery Market, By Application
6.1 Pain Management
6.2 Insulin Delivery for Diabetes
6.3 Vaccine Delivery
6.4 Pediatric Injections )
6.5 Obstructive Sleep Apnea
6.6 Other Applications
6.6.1.1 Angina
6.6.1.2 Hypertension
6.6.1.3 Other Medical Conditions
7 Needle Free Drug Delivery Market, By Geography
8 Key Player Activities
8.1 Mergers & Acquisitions
8.2 Partnerships, Joint Venture's, Collaborations and Agreements
8.3 Product Launch & Expansions
8.4 Other Activities
9 Leading Companies
9.1 3M Pharmaceuticals
9.2 Akra Dermojet
9.3 Antares Pharma, Inc.
9.4 AstraZeneca Plc
9.5 BioJect Medical Technologies, Inc.
9.6 D'Antonio Consultants International, Inc.
9.7 GlaxoSmithKline Plc (GSK)
9.8 Glide Pharmaceutical Technologies Ltd
9.9 Injex Pharma AG
9.10 Merck & Co.
9.11 Mylan Inc.
9.12 Novatis
9.13 Penjet Corporation
9.14 PharmaJet
9.15 Sanofi
9.16 Valeritas
9.17 Zogenix, Inc.
For more information about this report visit http://www.researchandmarkets.com/research/mgbrkv/needle_free_drug
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Drug Delivery, Infusions and Injectables


Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Anta Sports Expands Global Footprint With Strategic Puma Stake
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 



